甲状腺未分化癌分子机制和治疗的研究进展  

Research progress on molecular mechanism and treatment for anaplastic thyroid carcinoma

作　　者：李尤 郭宏鹏 张艺彤 刘俊良 俞建华 张金辉 孙成林[1] LI You;GUO Hongpeng;ZHANG Yitong;LIU Junliang;YU Jianhua;ZHANG Jinhui;SUN Chenglin(Department of General Surgery,The Center Hosipital Affiliated to Shenyang Medical College,Shenyang 110024,China;Department of General Surgery,The Center Hosipital of Shenyang Sujiatun)

机构地区：[1]沈阳医学院附属中心医院普外科,辽宁沈阳110024 [2]沈阳市苏家屯区中心医院普外科

出　　处：《沈阳医学院学报》2024年第3期309-315,共7页Journal of Shenyang Medical College

基　　金：辽宁省科学技术计划重大科研项目(No.2022JH2/101300035);沈阳市科技计划项目基金(No.21-173-9-18)。

摘　　要：甲状腺未分化癌(anaplastic thyroid carcinoma,ATC)是最具侵袭性的恶性肿瘤,预后极差。ATC发病机制复杂,目前尚无有效的治疗手段。近年来,随着对驱动ATC遗传(如BRAF V600E、TP53、TERT、PIK3CA突变等)和表观遗传(如组蛋白甲基化、组蛋白去乙酰化、microRNA调节通路等)改变的深入了解,分子靶向治疗为ATC患者带来新的希望。本文综述了ATC发病分子机制、靶向治疗和其他治疗的最新成果。Anaplastic thyroid carcinoma(ATC)is the most aggressive malignancy with poor prognosis.The pathogenesis of ATC is complex,and there is no effective treatment at present.In recent years,with the deep understanding of the genetic(such as BRAF V600E,TP53,TERT,PIK3CA mutations,etc.)and epigenetic(such as histone methylation,histone deacetylation,microRNA regulatory pathways,etc.)changes driving ATC,molecular targeted therapy has brought new hope to ATC patients.This article reviews the molecular mechanisms of ATC and the latest achievements in targeted therapy and other therapies.

关 键 词：甲状腺未分化癌 基因突变 靶向治疗 

分 类 号：R736.1[医药卫生—肿瘤]